Tozorakimab

Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease[1].

Product Specifications

CAS Number

[2376858-66-9]

Product Name Alternative

MEDI-3506

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tozorakimab.html

Purity

98.82

Solubility

H2O

Smiles

[Tozorakimab]

Molecular Weight

(144.66 kDa)

References & Citations

[1]Reid F, et al. Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease. American Thoracic Society. 2022: A2398-A2398. |[2]England E, et al. Tozorakimab (MEDI3506) : an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13 (1) :9825.